Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.
Department of Clinical Science, Intervention and Technology, Division of Surgery, Karolinska Institute, Stockholm, Sweden.
Ann Surg. 2020 Nov;272(5):684-689. doi: 10.1097/SLA.0000000000004340.
To investigate if prolonged TTS after completed nCRT improves postoperative outcomes for esophageal and esophagogastric junction cancer.
TTS has traditionally been 4-6 weeks after completed nCRT. However, the optimal timing is not known.
A multicenter clinical trial was performed with randomized allocation of TTS of 4-6 or 10-12 weeks. The primary endpoint of this sub-study was overall postoperative complications defined as Clavien-Dindo grade II-V. Secondary endpoints included complication severity according to Clavien-Dindo grade IIIb-V, postoperative 90-day mortality, and length of hospital stay. The study was registered in Clinicaltrials.gov (NCT02415101).
In total 249 patients were randomized. There were no significant differences between standard TTS and prolonged TTS with regard to overall incidence of complications Clavien-Dindo grade II-V (63.2% vs 72.6%, P = 0.134) or regarding Clavien-Dindo grade IIIb-V complications (31.6% vs 34.9%, P = 0.603). There were no statistically significant differences between standard and prolonged TTS regarding anastomotic leak (P = 0.596), conduit necrosis (P = 0.524), chyle leak (P = 0.427), pneumonia (P = 0.548), and respiratory failure (P = 0.723). In the standard TTS arm 5 patients (4.3%) died within 90 days of surgery, compared to 4 patients (3.8%) in the prolonged TTS arm (P = 1.0). Median length of hospital stay was 15 days in the standard TTS arm and 17 days in the prolonged TTS arm (P = 0.234).
The timing of surgery after completed nCRT for carcinoma of the esophagus or esophagogastric junction, is not of major importance with regard to short-term postoperative outcomes.
研究完全新辅助放化疗(nCRT)后延长时间点(TTS)是否能改善食管和食管胃交界部癌症患者的术后结局。
TTS 传统上是在完全 nCRT 后 4-6 周,但最佳时机尚不清楚。
进行了一项多中心临床试验,患者随机分配 TTS 为 4-6 周或 10-12 周。本研究的主要终点是定义为 Clavien-Dindo 分级 II-V 的总体术后并发症。次要终点包括根据 Clavien-Dindo 分级 IIIb-V 的并发症严重程度、术后 90 天死亡率和住院时间。该研究在 Clinicaltrials.gov 注册(NCT02415101)。
共随机分配了 249 例患者。标准 TTS 和延长 TTS 在总体并发症发生率(Clavien-Dindo 分级 II-V:63.2% vs 72.6%,P = 0.134)或 Clavien-Dindo 分级 IIIb-V 并发症发生率(31.6% vs 34.9%,P = 0.603)方面无显著差异。标准 TTS 和延长 TTS 之间在吻合口漏(P = 0.596)、移植物坏死(P = 0.524)、乳糜漏(P = 0.427)、肺炎(P = 0.548)和呼吸衰竭(P = 0.723)方面也无统计学差异。在标准 TTS 组中,有 5 例(4.3%)患者在手术后 90 天内死亡,而在延长 TTS 组中,有 4 例(3.8%)患者死亡(P = 1.0)。标准 TTS 组的中位住院时间为 15 天,延长 TTS 组为 17 天(P = 0.234)。
对于食管或食管胃交界部癌患者,完成新辅助放化疗后手术时间对短期术后结局没有重要影响。